Trial Profile

A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndrome

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QRX 003 (Primary)
Indications Netherton Syndrome
Focus Expanded access; Registrational; Therapeutic Use
Sponsors Quoin Pharmaceuticals

Most Recent Events

26 Mar 2026 According to a Quoin Pharmaceuticals media release, the company anticipates reporting topline data in the second half of 2026. Quoin plans to submit a New Drug Application (NDA) in the United States and other territories in late 2026/early 2027, subject to successful clinical outcomes.
20 Jul 2025 Planned End Date changed from 30 Apr 2026 to 30 Jul 2026.
20 Jul 2025 Planned primary completion date changed from 30 Apr 2026 to 30 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com